Detection of p73 antibodies in patients with various types of cancer: immunological characterization

por Tominaga, O, Unsal, K, Zalcman, G, Soussi, T
Publicado 2001

Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.

por Schlichtholz, B., Trédaniel, J., Lubin, R., Zalcman, G., Hirsch, A., Soussi, T.
Publicado 1994

Omicron variant: A clear and present danger for patients with cancer

por Barrière, J., Zalcman, G., Fignon, L., Peiffer-Smadja, N., Audigier-Valette, C., Carles, M.
Publicado 2022

Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête: Patients with chest cancer and COVID-19: at the heart of the storm

por Gounant, V., Brosseau, S., Soussi, G., Pluvy, J., Guezzour, N., Vauchier, C., Brouk, Z., Namour, C., Zalcman, G.
Publicado 2021

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

por Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazières, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A.-C., Westeel, V., Wislez, M.
Publicado 2020

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

por Girard, N., Galland-Girodet, S., Avrillon, V., Besse, B., Duruisseaux, M., Cadranel, J., Otto, J., Prevost, A., Roch, B., Bennouna, J., Bouledrak, K., Coudurier, M., Egenod, T., Lamy, R., Ricordel, C., Moro-Sibilot, D., Odier, L., Tillon-Strozyk, J., Zalcman, G., Missy, P., Westeel, V., Baldacci, S.
Publicado 2022

1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management

por Lièvre, A., Turpin, A., Ray-Coquard, I.L., Le Malicot, K., Thariat, J., Ahle, G., Mathieu, R., Sebbagh, V., Debieuvre, D., Canellas, A., Garcia-Larnicol, M-L., Colle, R., Hardy-Bessard, A-C., Mansi, L., Bourhis, J., Gorphe, P., Ursu, R., IDBAIH Ahmed, A., Zalcman, G., Bouche, O.
Publicado 2020

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of...

por Couraud, S., Cortot, A. B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G. R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., Milleron, B.
Publicado 2013

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

por Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Publicado 2019